Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccination with Nivolumab and Ipilimumab in Melanoma
NCT04382664Phase 2Completed
- Sponsor
- Ultimovacs ASA
- Start
- May 2020
- Primary completion
- Jan 2024
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of UV1 in Malignant Melanoma (MM) (2 arms), sponsored by Ultimovacs ASA. Primary endpoint: Progression-Free Survival up to 44 months. Started May 2020; status: completed.
02
Drugs
UV1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04382664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382664.